Aquestive Therapeutics (AQST) Income towards Parent Company (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Income towards Parent Company of -$8.1 million for Q1 2026, up 64.86% year-over-year from -$4.9 million in Q1 2025, and up 74.71% quarter-over-quarter from -$31.9 million in Q4 2025.
Aquestive Therapeutics (AQST) Income towards Parent Company (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Income towards Parent Company history runs 10 years deep, the most recent figure standing at -$8.1 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 64.86% year-over-year to -$8.1 million; the TTM figure through Mar 2026 stood at -$68.9 million (down 27.05% YoY), while the FY2025 annual figure was -$83.8 million, down 89.83% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$8.1 million, up from -$31.9 million in the prior quarter.
- The five-year high for Income towards Parent Company was $8.1 million in Q1 2023, with the low at -$31.9 million in Q4 2025.
- The 5-year median for Income towards Parent Company is -$12.5 million (2022), against an average of -$11.7 million.
- The sharpest annual moves came in 2023 and 2024: Income towards Parent Company jumped 161.03% in 2023, then tumbled 465.55% in 2024.
- Aquestive Therapeutics' Income towards Parent Company stood at -$12.4 million in 2022, then soared by 34.33% to -$8.1 million in 2023, then tumbled by 110.27% to -$17.1 million in 2024, then slumped by 86.81% to -$31.9 million in 2025, then jumped by 74.71% to -$8.1 million in 2026.
- Business Quant data shows AQST's Income towards Parent Company at -$8.1 million in Q1 2026, -$31.9 million in Q4 2025, and -$15.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Aquestive Therapeutics | 553.72 Mn | 553.72 Mn | 9.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.86 Mn |
| Mar 31, 2026 | -8.06 Mn |
| Dec 31, 2025 | -31.86 Mn |
| Sep 30, 2025 | -15.45 Mn |
| Jun 30, 2025 | -13.55 Mn |
| Mar 31, 2025 | -22.93 Mn |
| Dec 31, 2024 | -17.06 Mn |
| Sep 30, 2024 | -11.51 Mn |
| Jun 30, 2024 | -2.75 Mn |
| Mar 31, 2024 | -12.83 Mn |
| Dec 31, 2023 | -8.11 Mn |
| Sep 30, 2023 | -2.04 Mn |
| Jun 30, 2023 | -5.79 Mn |
| Mar 31, 2023 | 8.07 Mn |
| Dec 31, 2022 | -12.35 Mn |
| Sep 30, 2022 | -12.54 Mn |
| Jun 30, 2022 | -16.30 Mn |
| Mar 31, 2022 | -13.22 Mn |
| Dec 31, 2021 | -28.95 Mn |
| Sep 30, 2021 | -14.56 Mn |